JMP Securities has increased the price target for Protagonist Therapeutics Inc PTGX from $28 to $35, with a Market Outperform rating. Protagonist Therapeutics announced topline results from the Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback